

A Phase Ib/II open label, multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)

Gary Middleton¹, James Spicer², Burak Aktas², Habana Dinizulu³, Richard H Wilson⁴, David J Harrison^{5,6}, Elisabeth Oelmann⁶, Jeff Bloss⁶, Fiona Thistlethwaite^{3,7}

- 1) Birmingham NHS Foundation Trust/University of Birmingham, UK
- 2) King's College London, Guy's Hospital, London, UK
- 3) The Christie NHS Foundation Trust
- 4) Beatson West of Scotland Cancer Centre/University of Glasgow, UK
- 5) University of St Andrews, UK
- 6) NuCana plc
- 7) University of Manchester, UK

Abstract

Background

NUC-3373 is a novel thymidylate synthase (TS) inhibitor designed to directly deliver the active anti-cancer metabolite fluorodeoxyuridine-monophosphate (FdUMP) intracellularly. In addition to being a potent TS inhibitor, NUC-3373 has also been shown to cause DNA damage and promote the release of damage-associated molecular patterns. These diverse mechanisms position NUC 3373 as a potentially effective combination partner for several other anti-cancer agents.

Methods

NuTide:303 is a Phase Ib/II open label, multi-arm, parallel cohort dose-finding and expansion study designed to evaluate optimal combination partners for NUC-3373. Module 1 planned to enroll up to 12 evaluable patients with advanced/metastatic solid tumors to determine the recommended dose for NUC-3373 in combination with leucovorin (LV) and pembrolizumab. Module 2 planned to enroll approximately 6-12 evaluable patients with advanced/metastatic non-small cell lung cancer (of any histology) or pleural mesothelioma to determine the recommended dose for NUC-3373 in combination with LV and docetaxel. A 3+3 dose escalation design was used in both modules, with safety parameters continually assessed and tumor assessments conducted at screening and every 8 weeks from C1D1 until progression.

Results

Thirteen patients were enrolled in Module 1, with 9 evaluable for response. No DLTs were observed in these heavily pre-treated PD-(L)1 experienced patients with a variety of different tumor types. Four patients remained on treatment for >3 months and 3 patients were ongoing at the time of data cut-off. An objective response rate of 22% and a disease control rate of 67%

were reported. NUC-3373 + LV + pembrolizumab was well tolerated, the most common treatment-related adverse events (AEs) were nausea, vomiting, and diarrhea and the majority of events were Grade 1 (100%) or 2 (85%). Four patients were enrolled in Module 2, with 3 evaluable for response. Two patients treated at the first dose level achieved stable disease and completed >6 months of treatment The most common treatment-related AEs were fatigue (n=4) and diarrhea (n=3) and the majority of events were Grade 1 (100%) or 2 (100%).

Conclusions

Preliminary results from Module 1 show signals of anti-cancer activity and tolerability, providing support for further exploration of this combination in the Phase II part of the study. Preliminary results from Module 2 suggest that the probability of being able to escalate to typical efficacious doses of docetaxel used in combination is low due to overlapping toxicity. Further modifications to include the use of a different taxane in this combination are currently being considered.

Supplementary Data

Table of Contents

<i>Definition of DLT</i>	3
<i>Summary of Patients</i>	4

Definition of DLT

DLT was defined as any of the following occurring during Cycle 1 (Module 1) or Cycles 1 and 2 (Module 2) that were not due to the protocol disease indication or to a known concurrent medical condition and were judged as clinically significant and related to study treatment.

For dose escalation, DLTs were defined as follows
Any Grade 4 AEs, with the exception of:
Neutropenia lasting <72 hours that is not associated with fever or other clinical symptoms
Lymphopenia
Electrolyte abnormalities that are not associated with clinical sequelae and are corrected with appropriate management or supplementation within 72 hours of the onset
Any Grade 3 AEs, with the exception of:
Nausea and vomiting persisting for <2 days after optimal anti-emetic therapy
Thrombocytopenia without significant bleeding (including platelet transfusions)
Diarrhea persisting for <2 days after optimal anti-diarrheal treatment
Hypertension persisting <7 days after treatment
Infection or fever in the absence of neutropenia persisting <5 days
Rash or photosensitivity persisting <7 days after treatment
Fatigue persisting <7 days
Liver function test elevations (AST/ALT) persisting <7 days after treatment with corticosteroids
Immune-related adverse events persisting <7 days after treatment with corticosteroids
Alopecia
The following Grade 2 AEs were to be adjudicated as DLTs:
Total bilirubin CTCAE v5 \geq Grade 2 with simultaneous ALT/AST CTCAE v5 \geq Grade 2
Pneumonitis persisting >7 days despite treatment with corticosteroids
Eye pain or reduction of visual acuity that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks of the initiation of topical therapy OR requires systemic treatment
Other clinically significant toxicities (cardiotoxicity, neurotoxicity) including a single event or multiple occurrences of the same event that lead to a dosing delay of >7 days in Cycle 1

Summary of Patients

Module 1		
Disease	Prior Treatment for Metastatic Disease	Metastatic Sites
NSCLC (squamous)	1. docetaxel	1 x lung
Sinonasal Carcinoma	0	1 x nose
Pleural Mesothelioma	1. ipilimumab + nivolumab	2 x pleura
Urothelial Bladder	1. gemcitabine + cisplatin 2. avelumab	2 x liver
Oropharyngeal (p16+)	1. nivolumab 2. investigational agent + atezolizumab	2 x lung 1 x mediastinum 2 x pelvis
Oropharyngeal	1. nivolumab	2 x lung 1 x mediastinum
Urothelial Bladder (Lynch Syndrome)	1. atezolizumab	1 x lung
Cutaneous Melanoma	1. pembrolizumab 2. dabrafenib + trametinib	1 x lymph node
Cutaneous Melanoma	1. ipilimumab + nivolumab	1 x lung 1 x liver 1 x mediastinum
Pancreatic Adenocarcinoma	1. FOLFIRINOX 2. gemcitabine + cisplatin	2 x liver
Anal (squamous)	1. paclitaxel + carboplatin 2. capecitabine + mitomycin c	2 x lung 1 x lymph node
NSCLC (squamous)	1. pembrolizumab	2 x lymph node 2 x lung
Cutaneous Melanoma	1. ipilimumab + nivolumab	1 x lymph node

Module 2

Disease	Prior Treatment for Metastatic Disease	Metastatic Sites
NSCLC (squamous)	1. carboplatin + paclitaxel + pembrolizumab	1 x lung
NSCLC (non-squamous)	1. pembrolizumab 2. carboplatin + pemetrexed	2 x non-lymph node
Pleural Mesothelioma	1. cisplatin + pemetrexed 2. nivolumab 3. carboplatin + pemetrexed	2 x lymph node 2 x mediastinum
NSCLC (non-squamous)	1. gemcitabine + cisplatin 2. atezolizumab	1 x lung 2 x lymph node 1 x muscle/soft tissue